Blog
RSS FeedPosted by Michael Wonder on 05 Mar 2021
ICER publishes final evidence report and policy recommendations on roxadustat
5 March 2021 - Independent appraisal committee determines the evidence is not adequate to demonstrate that roxadustat provides a net ...
Posted by Michael Wonder on 05 Mar 2021
PBAC Public Summary Documents - November 2020 meeting
5 March 2021 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the November 2020 PBAC ...
Posted by Michael Wonder on 04 Mar 2021
Create a U.S. Institute of Health Technology Assessment to preserve innovation and control costs
2 March 2021 - The public outcry to “do something” about health care spending keeps growing, but fear about what that ...
Posted by Michael Wonder on 04 Mar 2021
Ofev (nintedanib) receives positive recommendation from CADTH and INESSS for the treatment of progressive fibrosing interstitial lung diseases
4 March 2021 - Ofev is the first treatment available in Canada for chronic fibrosing interstitial lung diseases with a progressive ...
Posted by Michael Wonder on 04 Mar 2021
The PHARMAC non-review?
4 March 2021 - The recently announced PHARMAC review is fatally flawed. ...
Posted by Michael Wonder on 04 Mar 2021
NICE rejects rare blood cancer treatment Poteligeo in final appraisal
4 March 2021 - The UK’s NICE has not recommended Kyowa Kirin’s Poteligeo for the treatment of adults living with ...
Posted by Michael Wonder on 03 Mar 2021
Cancer patient told palliative care only option after being rejected PHARMAC funding
2 March 2021 - The drug-buying agency was placed under an independent review today after the Prime Minister said she ...
Posted by Michael Wonder on 03 Mar 2021
PHARMAC ripe for reassessment
3 March 2021 - New Zealand’s drug buying agency PHARMAC has long been, simultaneously, a good thing in itself and ...
Posted by Michael Wonder on 03 Mar 2021
NICE backs NHS use of Lilly’s Olumiant in eczema
3 March 2021 - Eli Lilly’s Olumiant has received a UK NICE recommendation for the treatment of moderate-to-severe atopic dermatitis ...
Posted by Michael Wonder on 02 Mar 2021
What could Biden’s possible bid for a national health technology assessment entity look like?
2 March 2021 - The U.S. has never had a publicly funded, independent health technology assessment organisation to evaluate prescription drugs, ...
Posted by Michael Wonder on 02 Mar 2021
ICER publishes Final Evidence Report and policy recommendations on new therapies for high cholesterol
2 March 2021 - For bempedoic acid, independent appraisal committee votes that the evidence is not adequate to demonstrate a net ...
Posted by Michael Wonder on 02 Mar 2021
Government announces review into PHARMAC
2 March 2021 - The Government is following through on an election promise to conduct an independent review into PHARMAC, ...
Posted by Michael Wonder on 02 Mar 2021
Medicines New Zealand supportive of Government’s PHARMAC review assuming it is not a box-ticking exercise
2 March 2021 - Medicines New Zealand is supportive of the proposed review into PHARMAC if it is intended to improve ...
Posted by Michael Wonder on 01 Mar 2021
Review asks how Government can get the new drugs it wants funded
2 March 2021 - The much-vaunted PHARMAC inquiry, being announced today, will investigate how the drug-buying agency can be brought ...
Posted by Michael Wonder on 01 Mar 2021
Nusinersen in spinal muscular atrophy: indication of considerable added benefit in children with an early onset of the disease
1 March 2021 - The treatment delays permanent ventilation of the children and extends life. In addition, the children develop more ...